CRDF

Cardiff Oncology, Inc.

1.08 USD

Last updated Sep 5, 12:03 UTC

Yesterday HIGH

$1.1

Yesterday LOW

$1.06

52w HIGH

$3.3

52w LOW

$0.76

EPS

-0.14

PE

-7.71

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Cardiff Oncology, Inc. stock is up 12.5% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.43% of the previous 22 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

21 Jul 13:43	21 Jan, 2028	1.50	CALL	2500	1605

Advanced Data Unlock

Benzinga Newsdesk

Mon Jun 1, 2026

TD Cowen Downgrades Cardiff Oncology to Hold

TD Cowen analyst Marc Frahm downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Hold.
Avi Kapoor

Mon Jun 1, 2026

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
Benzinga Newsdesk

Mon Jun 1, 2026

HC Wainwright & Co. Downgrades Cardiff Oncology to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Cardiff Oncology (NASDAQ:CRDF) from Buy to Neutral.
Benzinga Newsdesk

Fri May 29, 2026

NMS Informs Cardiff Oncology Of Agreement Termination On May 27, 2026; NMS Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship; NMS Alleges Failure By Cardiff Oncology To Use Commercially Reasonable Efforts For Onvansertib; Cardiff Oncology States NMS Termination Notice Is Ineffective And Will Continue Under Agreement

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001213037/000119312526248711/crdf-20260527.htm
Benzinga Newsdesk

Thu May 21, 2026

Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC

Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of
Vandana Singh

Wed May 20, 2026

Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense

Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed Cardiff's legal stance.
Benzinga Newsdesk

Thu May 14, 2026

Cardiff Oncology Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $41.000K Miss $85.000K Estimate

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 10 percent increase over losses of $(0.20) per share from the
Benzinga Newsdesk

Tue Apr 21, 2026

Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology

Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized
Benzinga Newsdesk

Fri Apr 17, 2026

Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026

Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American
Benzinga Newsdesk

Thu Apr 9, 2026

Cardiff Oncology Appoints Mani Mohindru As President And Chief Executive Officer; Josh Muntner Appointed As CFO

Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the appointment of Mani Mohindru, PhD, as